MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mannitol 5% W/ Dextrose 5% In Sodium Chloride 0.12%, and what generic alternatives are available?
Mannitol 5% W/ Dextrose 5% In Sodium Chloride 0.12% is a drug marketed by B Braun and is included in one NDA.
The generic ingredient in MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is mannitol. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mannitol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%?
- What are the global sales for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%?
- What is Average Wholesale Price for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%?
Summary for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 225 |
| DailyMed Link: | MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% at DailyMed |
Recent Clinical Trials for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Geneva | Phase 3 |
| Morten Hostrup, PhD | N/A |
| Centre Hospitalier Universitaire Vaudois | Early Phase 1 |
See all MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% clinical trials
US Patents and Regulatory Information for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun | MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% | mannitol | INJECTABLE;INJECTION | 016080-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252 Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. |
Authorised | no | no | no | 2012-04-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
